For health professionals: Avian influenza A(H7N9)
Find detailed information for health professionals.
On this page
Health professionals are reminded to refer to their provincial or territorial Ministry of Health for specific recommendations on surveillance and public health.
Relevant laboratory guidance and identified protocols can be found in the Protocol for Microbiological Investigations of Severe Acute Respiratory Infections (SARI).
Public health authorities in Canada are advised to continue vigilance for the recognition, reporting and prompt investigation of patients with SARI or severe influenza-like illness (ILI).
Antiviral drugs such as oseltamivir or zanamivir can reduce the duration of illness and improve the prospect of survival if administered within 48 hours of illness onset.
The following resources provide additional information on the clinical management of human infection with avian influenza A(H7N9) virus:
For more information
- Public Health Agency of Canada Expert Panel on Avian Influenza A(H5Nx) in Canada
- Public Health Management of Human Illness Associated with Avian Influenza A(H7N9) Virus: Interim Guidance for Containment when Imported Cases with Limited Human-to-Human Transmission are Suspected/Confirmed in Canada
- Emerging Respiratory Pathogens and Severe Acute Respiratory Infection (SARI) Case Report Form
- Joint Biosafety Advisory: Influenza A(H7N9) Virus - March 17, 2014
- World Health Organization: Situation updates - Avian influenza
- National Case Definition: Avian Influenza A(H7N9) Virus
- Date modified: